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Abstract
A report of the 6th Epigenomics of Common Diseases Conference held at the Wellcome Genome Campus in
Hinxton, Cambridge, UK, on 1–4 November 2016.
Introduction
Epigenetic modification provides a stable mechanism by
which cells with the same genotype can modulate their
gene expression and exhibit different phenotypes. In the
past two decades, excellent progress has been made to
profile these modifications and our understanding of
epigenetic marks has surpassed beyond the basic
phenomenon of cellular heterogeneity. It is now estab-
lished that epigenetic marks are altered in almost all
common human diseases. The Epigenomics of Common
Diseases meeting, 1–4 November 2016, provided an
account of the progress made in this area and also indi-
cated future areas that are yet to be addressed. Although
disease focussed, several other aspects were discussed
that are relevant to epigenetics as a field, including cellu-
lar heterogeneity, epigenomic association studies, emer-
ging concepts in cancer epigenetics and new innovative
techniques of broad application (such as single-cell ana-
lysis and epigenomic editing approaches). Here, we pro-
vide a brief report of some of the key ideas and themes
discussed in this meeting and based on these, we specu-
late on future research directions.
A needle in the haystack: insights from epigenome-wide
association studies
Recent advances in high-throughput DNA analysis now
enable researchers to examine epigenetic modifications
across the genome, primarily DNA methylation marks,
for association with numerous disease phenotypes. As
such, epigenome-wide association studies (EWASs) have
been fruitful in their findings but they also harbour their
own unique challenges. EWASs provide an opportunity
to investigate a large number of CpGs across large num-
bers of patients and controls to detect aberrant methyla-
tion signals at a population level [1]. Further, EWASs are
an ideal platform to tap into large international resources
and compare multiple datasets with custom-generated
EWAS data. Examples of well-curated epigenomic data-
sets include the International Human Epigenome Consor-
tium (IHEC), the EU-funded BLUEPRINT project, and
the International Cancer Genome Consortium (ICGC).
Although EWASs have been in use for several years now
and thousands of datasets and several analytical tools have
been reported, there is still a need to understand the po-
tential biases and the nature of factors that could influence
the interpretation of results. More sophisticated tools need
to be developed to account for these factors. One observa-
tion to come out of this meeting, based on the commen-
tary of multiple speakers, was that EWASs require robust
analytical tools to detect epigenetic variants of interest
and to adjust for confounding factors such as genetic
effects and cellular heterogeneity.
Several speakers presented vignettes of many interest-
ing EWAS findings, including Stephan Beck (University
College London, UK) who shared some “new twists” in
EWAS analytics and started off with a plea for authors
and editors alike to ensure EWAS papers include CpG
numbers. This oversight, he suggested, was akin to pub-
lishing a genome-wide association study without includ-
ing rs numbers for single-nucleotide polymorphisms.
Methylation of a CpG site and its relationship to the
expression of a corresponding or nearby gene is very
context specific. For example, the methylation of a par-
ticular gene promoter is likely to be very different to the
methylation of the gene body. Methylation in either of
these elements could have a different function for the
specificity of the corresponding transcription [2]. There-
fore, providing the methylation of a gene as a whole is
almost meaningless if the context (i.e. the CpG number)
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is not described. In their analysis of >700 haemopoietic
effector cell methylomes from monozygotic twins dis-
cordant for type 1 diabetes, Beck and colleagues were
only able to identify a single significant differentially
methylated CpG position (DMP). Undeterred, they
shifted their focus from differences in mean methylation
and used a novel approach to detect differentially vari-
able positions (DVPs). The diabetes-associated DVPs
were temporally stable and mapped onto regulatory cir-
cuits involved in cell cycle and immune cell metabolism.
Similarly, they also applied this approach to methylomes
from monozygotic twins discordant for rheumatoid arth-
ritis and also to the discovery of DNA methylation and
gene expression variability in normal blood cells. Sub-
stantial DNA methylation and gene expression variation
in normal blood cells has also been reported in recent
genome-wide studies [3–5]. Therefore, it is important to
consider the normally occurring variation in methylomes
for detecting differential methylation signals. Beck also
presented several bioinformatic tools for EWAS inter-
pretation such as eFORGE (http://eforge.cs.ucl.ac.uk),
which identifies tissue or cell-type specific signals from
Illumina 450K methylation array data [6], EpiDISH (freely
available from https://github.com/sjczheng/EpiDISH),
which can be used for epigenetic dissection of heterogen-
eity within a sample, and CORALINA (comprehensive
guide RNA library generation through controlled nuclease
activity), a universal method for generating guide RNA
libraries for large-scale CRISPR-based genomic and epige-
nomic screening [7].
Bill Cookson (Imperial College London, UK) presented
an EWAS of total serum immunoglobulin E (IgE), which
is a central mediator in asthma and atopy, in peripheral
blood leukocyte methylomes [8]. Of the 36 loci showing
an association between methylation and IgE concentration,
several loci were annotated to genes related specifically to
eosinophil function (e.g. IL5RA), which is consistent with
the presence of activated eosinophils in atopic subjects.
Notably, a monoclonal antibody targeted to IL5RA is
currently in phase 3 trials for the treatment of severe
asthma. Cookson reiterated the point that cell hetero-
geneity and genetic factors need to be accounted for
in EWASs. The WCGNA package (freely available
from https://labs.genetics.ucla.edu/horvath/Coexpression
Network/Rpackages/WGCNA/) that was used to account
for cellular heterogeneity in this study was suggested as an
alternative to other more established methods that adjust
for cell mixtures in the analysis of DNA methylation data.
Also from Imperial College London, UK, John Chambers
reported findings from the EpiMigrant study, which investi-
gated changes in DNA methylation patterns associated with
high risk of type 2 diabetes in South Asians [9]. Methylation
markers identified at five loci were found capable of pre-
dicting future onset of diabetes independently of other
known risk factors. The genes associated with three of these
loci (TXNIP, ABCG1, and SREBF1) have biological plausi-
bility in the context of type 2 diabetes. In an EWAS investi-
gating adiposity, methylation markers at 187 loci were
found to be associated with body mass index (BMI) [10].
These loci were enriched for functional regulatory elements
and gene promoters that mapped to biologically plausible
pathways. However, Mendelian randomisation to test for
causal relationships indicated that the changes in methyla-
tion were more likely to be a consequence rather than a
cause of BMI.
Epigenetics in cancer
The mechanisms involved in the hallmark properties of
a cancer cell are well described and continue to be heav-
ily investigated [11]. Until recently, cancer was often per-
ceived as only a disease of the genome. However, it is
now established that epigenetic changes are present in
all human tumours and the fact that cancer is a disease
of both the genome and epigenome is gaining recogni-
tion. The analysis of thousands of cancer genomes re-
vealed that epigenomic regulator genes were often
mutated in many cancers [12]. Epigenetic alterations
have been shown to cooperate with genetic alterations
to drive the cancer phenotype [13]. These changes can
be used as biomarkers of disease state and the poten-
tially reversible nature of epigenetic aberrations has been
an alluring prospect for the field of epigenetic therapies.
In her talk on epigenetics of the cancer microenviron-
ment, Susan Clark (Garvan Institute of Medical Re-
search, Sydney, Australia) began by quoting Stephen
Paget’s 1889 “soil and seed hypothesis”—“When a plant
goes to seed, its seeds are carried in all directions; but
they can only live and grow if they fall on congenial
soil”. The focus of Clark’s investigation was on pro-
tumorigenic cancer-associated fibroblasts (CAFs), which
in vitro studies have shown, were not just transiently ac-
tivated by signalling from tumour cells but they retain
their phenotype even when tumour cell stimuli were re-
moved. Whole-genome bisulfite sequencing (WGBS)
and RNA-Seq were used on CAFs from prostate cancer
and compared to matched non-malignant prostate fibro-
blasts (NPFs). This comparison showed a large number of
discrete differentially methylated regions (DMRs), mainly
hypomethylated, that were enriched at promoters and en-
hancers. A subset of DMRs shared methylation changes
with tumour epithelial cells, suggesting convergent epi-
genetic programming. These robust biomarkers show
promise for improved early prostate cancer diagnosis.
Peter Jones (Van Andel Research Institute, MI, USA)
shared some compelling findings that support treating
haematological and other cancers with a combination of
epigenetic therapy, e.g. the DNA methylation inhibitor
5-aza-2′-deoxycytidine, and physiological levels of
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vitamin C. From in vitro studies of cancer cells, this
combination treatment was shown to synergistically in-
hibit proliferation and increase apoptosis by enhanced
demethylation of endogenous retroviruses (ERVs). The
subsequent increased expression of ERVs stimulated im-
mune signalling leading to apoptosis. Interestingly, it has
been recently shown that treatment of ovarian cancer
cell lines with a DNA methylation inhibitor triggered
double-stranded RNA (dsRNA) sensing in the cytoplasm
causing a type I interferon response and apoptosis. This
response was associated with upregulation of hyper-
methylated ERV elements. They also observed a similar
event in melanoma [14]. Taken together, these findings
indicate that understanding the consequences of de-
methylation treatment in large genomic segments such
as repeat elements (for example, ERVs) provide new op-
portunities to modulate the cancer epigenome and
phenotype, resulting in better responses to new treat-
ments such as immunotherapy. Further, Jones suggested
that the enhanced ERV demethyltion effect was a result
of both passive demethylation by 5-aza-2′-deoxycytidine
and active demethylation by the TET family of enzymes,
of which Vitamin C is a cofactor. Indeed, the ERV-
induced response was blunted in TET2 knockout cells.
As approximately 60% of cancer patients are significantly
vitamin C deficient, these findings suggest that the re-
sponse to epigenetic therapy in many patients could be
improved by correcting for this deficiency.
Manel Esteller (Bellvitge Biomedical Research Insti-
tute, Barcelona, Spain) was able to showcase a large
amount of impressive work to come out of his lab re-
cently. These included a genome-wide DNA methylation
analysis of cell lines derived from the primary melanoma
tumour and matched lymph node metastasis from the
same individual. From this analysis, Esteller and colleagues
discovered that hypomethylation-associated reactivation
of a cryptic 47kDa transcript of TBC1D16 promotes mel-
anoma growth and metastasis and in a clinical setting is
associated with poor prognosis [15]. In an effort to explore
regulatory regions outside classical coding and promoter
regions, they have also used WGBS to identify cancer-
associated DNA methylation aberrations in super-
enhancers [16]—key regulatory regions associated with
cell identity and function [17]. Of interest, in a later talk,
Francois Spitz (Institut Pasteur, Paris) indicated that a
super-enhancer can actually be a clustered collection of
distinct specific enhancer molecules. Esteller also intro-
duced a valuable resource that provides insight into phar-
macogenomic interactions in cancer [18]. By mapping a
large number of cancer-specific alterations from tumour
tissues (mutations, copy number alterations, DNA methyla-
tion, and gene expression) onto well-annotated human can-
cer cell line pharmacogenomic datasets, it was found that
the cell line data reliably recapitulated the cancer-specific
alterations in tumours and could be used to predict drug
sensitivity or resistance. Wrapping up, Esteller presented an
analysis that used DNA methylation profiling of 2790 tu-
mours with an unknown primary origin to establish a pre-
dictive classifier of the original primary tumour site. The
predictive classifier was validated in a cohort of 7691
tumour samples with high specificity and selectivity [19].
Duncan Sproul (MRC Human Genetics Unit, University
of Edinburgh, UK) described a work that used WGBS in
oestrogen receptor-positive breast tumours to explore
causes of widespread DNA hypomethylation in cancer.
These tumours were specifically hypomethylated at large
partially methylated domains (PMDs) that replicated in
late S-phase and were associated with dysfunctional DNA
methyltransferases. Loss of the de novo DNA methyl-
transferase DNMT3B resulted in preferential hypomethy-
lation of PMDs, whereas loss of the maintenance DNA
methyltransferase DNMT1 resulted in genome-wide hy-
pomethylation. Furthermore, hypomethylation of PMDs
was correlated with an increase in copy number variations
that would contribute to chromosome instability in these
tumours. Although the existence of PMDs in cancer cells
and somatic cells has been described and analysed in sev-
eral studies using different methods [20–23], their role in
carcinogenesis is still unclear. One possibility is that the
formation of PMDs could explain the potential mechan-
ism of global hypomethylation observed in the cancer
genome; however, reproducible functional studies need to
be conducted in the future to establish the role of PMDs.
One technical aspect of genome-wide methylation
profiling that was evident from both Susan Clark’s and
Duncan Sproul’s talks was the power of using WGBS. Al-
though 450K or 850K are very reproducible and are feas-
ible platforms for large-scale EWAS, it was clear that large
genomic methylation changes could escape detection of
these array platforms, which have representative CpG
probes for specified regions. For example, the use of
WGBS enabled the detection of PMDs in breast cancer as
discussed by Sproul. Susan Clark showed examples of
some large regions showing differential methylation in
prostate cancer, and this detection would not be possible
with the existing array platforms. Sequencing-based
genome-wide methods such as reduced representation bi-
sulfite sequencing (RRBS) and WGBS are also more likely
to detect methylation aberrations in regions distant from
coding genes. Although the cost of WGBS is still substan-
tially very high to be applied for large-scale studies at the
moment, these techniques can be used for more niche
questions on limited samples to gain biological insight for
further exploration.
Innovative epigenomic approaches
The field of epigenomics continues to rapidly expand,
which is aided by researchers embracing or even developing
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new techniques and technologies to decipher unanswered
questions. Two of the most exciting concepts to emerge
recently are the use of single-cell profiling and targeted epi-
genetic genome editing using the CRISPR/Cas9 system.
Wolf Reik (Babraham Institute, Cambridge, UK) has
used single-cell epigenomic profiling of embryonic stem
cells (ESCs) to explore the relationship of epigenetic
heterogeneity and cell fate decisions in mammalian de-
velopment. DNA methylation analysis of naïve compared
to primed ESCs showed the greatest methylation hetero-
geneity in enhancer elements. By modelling DNA
methylation in primed ESCs, Reik suggested that oscilla-
tions of methylation and demethylation by the DNMT3
enzymes and the TET enzymes could explain the tran-
scriptional heterogeneity observed in primed ESCs.
Single-cell sequencing revealed global regulation of het-
erogeneity at gastrulation. The absence of “translational
substructure” in the primed states indicated transcrip-
tional noise was at a peak prior to major cell fate deci-
sions. Reik concluded by briefly introducing a new
single-cell method based on NOMe-Seq [24] that incor-
porates chromatin accessibility, methylation, and tran-
scriptome analysis.
Continuing on in a similar vein, John Marioni (EMBL-
EBI, Wellcome Genome Campus, UK) used single-cell
RNA-Seq to explore cell fate decisions in early embryo
development. Analysis of mouse embyros captured from
early gastrulation to primitive erythrocyte formation
identified ~2000 highly variable genes that were allo-
cated to ten distinct clusters. Repeating this approach in
Tal1 knockouts allowed sharper insight into whether this
cell fate decision followed a step-wise restriction model
[25]. In another study, Marioni and colleagues used
single-cell sequencing of unstimulated CD4+ T cells in
mice, which showed that T cell activation triggers a tran-
scriptional switch from stochastic to tightly regulated
gene expression. In older animals, the core activation
program was expressed at a lower average upon immune
stimulation. Further, ageing significantly perturbed the
activation of the core program and increased variability
between cells.
Emily Saunderson (Barts Cancer Institute, Queen
Mary University of London, UK) from the laboratory of
Gabriella Ficz presented a study that targeted a CRISPR/
Cas9 DNMT 3A/3L fusion to a panel of genes in pri-
mary breast myoepithelial cells. The hypermethylation-
associated repression of RASSF1 and CDKN2A resulted
in increased cell proliferation. Outgrowing cells were not
immortalized, but they escaped senescence. Interestingly,
targeting the CpG islands of both CDKN2A gene prod-
ucts, p16 and p14, but not individually allowed the cells
to escape senescence.
Daniel Ibrahim (Charité—Universitätsmedizin Berlin,
Germany) and colleagues used CRISPR/Cas9 in mice to
recapitulate genomic duplications at the Sox9 locus that in
humans caused female to male sex reversal when the du-
plications were contained within a non-coding chromatin-
partitioning unit called a topologically associated domain
(TAD). Capture Hi-C and 4C-seq analysis showed that
intra-TAD duplications resulted in sex reversal and no
overall change in TAD conformation. However, in contrast,
inter-TAD duplications across TAD-boundaries were asso-
ciated with a normal phenotype due to an insulation effect
and new chromatin domains called neo-TADs were
formed. However, when inter-TAD duplications included
an adjacent potassium channel, Kcnj2, the duplicated gene
was now located inside the neo-TAD and misexpressed by
the Sox9 regulatory landscape which caused a different dis-
ease, Cooks Syndrome [26].
Rieke Kempfer (Max Delbrück Center for Molecular
Medicine, Berlin-Buch, Germany) from the Epigenetic
Regulation and Chromatin Architecture laboratory of Ana
Pombo introduced a novel cryosectioning-based method,
genome architecture mapping (GAM), that can be used to
explore relationships between 3D interactions and gene
expression. This method has been applied to mouse ESCs,
where specific domains have shown enrichment for inter-
actions between distant enhancers and actively expressed
genes. It is hoped that this method, which achieves 30 kbp
resolution using as little as 400 cells, can be applied to a
clinical setting in the future [27].
Concluding remarks
In conclusion, this meeting covered many different con-
cepts and new developments in the area of disease epi-
genetics. One aspect that generated some discussion was
the correction for cellular composition in epignenetic
profiling. Although sophisticated algorithms have been
developed in the last few years to correct for methyla-
tion bias due to cell composition in the blood, it was
clear from the discussion that the existing methods are
far from perfect. It is important to note this potential
bias as a result of mixed cell type, rather than assuming
that the algorithms will provide the ideal results. This is
particularly important as the blood continues to be the
most widely used tissue for any epigenomic study (for
example, in neurological diseases it is assumed to be a
good surrogate for brain tissue, which is of course diffi-
cult to obtain). For other cell types (such as from the
kidney, the skin), the methods are yet to be developed
for cell composition correction. In summary, although
hundreds of reference methylomes are now available,
correcting for methylation biases due to cell composition
continue to pose substantial challenges.
DNA methylation is generally perceived as a suppres-
sive mechanism, and this perception was developed with
the repeated observation of gene silencing due to pro-
moter methylation. However, as we are now able to
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profile methylation at a genome-scale (i.e., beyond the
promoter), it is becoming clear that the relationship of
methylation with gene expression is more complex than
the simple assumption of negative regulation of expression
by promoter methylation. In fact, from several talks, it be-
came clear that methylation changes alter distal regulatory
elements, particularly enhancers, which could result in
large changes to the transcriptional program. Talks from
cancer epigenetics also highlighted the importance of inves-
tigating the relationship between DNA methylation and re-
peat elements. Currently, little is known about methylation
and the regulation of distant elements and future research
is likely to reveal more on the nature of these relationships.
It was also evident from the meeting that the develop-
ment of new tools and approaches is an active area of re-
search in this field. Especially with the release of many
publicly available datasets, it is important to develop new
tools that are accessible to biologists as eventually it has to
be useful for them to address their research questions.
From this meeting, it was evident that exciting research
on understanding the basis of epigenomics of common
disease will continue to take place in the future.
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